Antidepressant drug use: Differences between psychiatrists and general practitioners. Results from a drug utilization observation study with fluoxetine

Pharmacopsychiatry

Volumn 30, Issue SUPPL. 1, 1997, Pages 28-34

  Dittmann, R W ^a,e   Linden, M ^b   Osterheider, M ^c   Schaaf, B ^d   Ohnmacht, U ^a   Weber, H J ^a  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Factum   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GERMANY; HUMAN; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; PSYCHIATRIST; SIDE EFFECT; TREATMENT PLANNING;

EID: 0031035306     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979514     Document Type: Article

References (20)

1. Beasley, C. M. Jr., B. E. Dornseif, J. C. Bosomworth, M. E. Sayler, A. H. Rampey Jr., J. H. Heiligenstein, V. L. Thompson, D. J. Murphy, D. N. Masica: Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br. Med. J. 303 (1991) 685-691
2. Beasley, C. M., J. H. Potvin, D. N. Masica, D. E. Wheadon, B. E. Dornseif, L. A. Genduso: Fluoxetine: no association with suicidality in obsessive-compulsive disorder. J. Aff. Dis. 24 (1992) 1-10
3. CPMP, Committee for Proprietary Medicinal Products (Ed.): Draft guideline for marketing authorisation holders on company-sponsored post-marketing safety studies III/3176/93, draft 3
4. Dittmann, R. W., et al.: Co-medication and rates of adverse events, an analysis from a drug surveillance study on fluoxetine use in Germany. (Submitted)
5. Freeman, H. (Ed.): Progress in antidepressant therapy. Fluoxetine: a comprehensive overview. Br. J. Psychiatry 153 (Suppl. 3) (1988) 7-112
6. Herbold, M., et al., (Ed.): Empfehlungen zur Planung, Durchführung und Ausweitung von Anwendungsbeobachtungen. AG "Pharmazeutische Forschung", Biometrische Gesellschaft (1994)
7. Kasper, S., S. A. Montgomery: Affective disorders - current and future perspectives. Int. Clin. Psychopharmacol. 8 (1993) 211-343
8. Levin, G. M., C. L. DeVane: Prescribing attitudes of different physician groups regarding fluoxetine. Ann. Pharmacother. 27 (1993) 1443-1446
9. Linden, M.: Phase-IV-Forschung, Springer, Berlin (1987)
10. Linden, M.: Die Phase IV der Therapie-Evaluation. Nervenarzt 60 (1989) 453-461
11. Linden M., D. Baier, H. Beitinger, R. Konnen, M. Osterheider, M. Philipp, P. E. Reimitz, B. Schaaf, H. J. Weber Leitlinien zur Durchführung von Anwendungsbeobachtungen (AWB) in der Psychopharmakotherapie. Nervenarzt 65 (1994) 638-644
12. Linden M., M. Osterheider, T. Nickelsen, B. Schaaf: Three types of early termination of antidepressant drug treatment. Int. Clin. Psychopharmacol. 8 (1993) 345-346
13. Linden, M., M. Osterheider, B. Schaaf, G. Fleckenstein, H. J. Weber: Fluoxetin in der Anwendung durch niedergelassene Nervenärzte. Münch. med. Wschr. 134 (1992) 836-840
14. Nickeisen, T., M. Linden, M. Osterheider, B. Schaaf: Therapie von Depressionen. Fluoxetin in der Allgemeinpraxis: eine Anwendungsbeobachtung. Z. Allg. Med. 69 (1993) 780-785
15. NIMH: Clinical Global Impressions. In: AMDP, CIPS (Eds.): Rating scales for psychiatry. European Edition. Weinheim Beltz-Test GmbH (1990)
16. Schaaf, B., et al.: An investigation of the representativity of neuropsychiatrists and their patients in a drug utilization study of fluoxetine. Pharmacopsychiat. 30 (1997) (Suppl. 1) 44-51
17. Stokes, P. E.: Fluoxetine: a five-year review. Clin. Ther. 15 (1993) 216-243
18. Teicher, M. H., C. Glod, J. O. Cole: Emergence of intense suicidal preoccupation during fluoxetine treatment. Am. J. Psychiatry 147 (1990)
19. Victor, N., H. Schäfer, H. Nowak (Eds.): Arzneimittelforschung nach der Zulassung. Bestandsaufnahme und Perspektiven. Springer, Berlin (1991)
20. Zung, W. W. K.: Self-Rating Depression Scale (SDS). In: CIPS (Ed.): Internationale Skalen für Psychiatrie. Beltz-Test GmbH, Weinheim (1981)